STOK - Stoke Therapeutics Inc

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.

52W High

$20.90

52W Low

$5.35

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.14

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

23.77

Forward P/E (<15 better)

204.08

EV/EBITDA (<8 favorable)

21.00

EV/Revenue (<3 favorable)

4.44

P/S (TTM) (<3 favorable)

5.67

P/B (<3 favorable)

3.38

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

4.46%

Institutions (25–75% balanced)

118.42%

Shares Outstanding

54,797,000

Float

38,187,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

199,893,000

Gross Profit (TTM)

199,893,000

EPS (TTM)

0.87

Profit Margin (>10% good)

0.26%

Operating Margin (TTM) (higher better)

-1.98%

ROE (TTM) (>15% strong)

0.18%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

1.86

Momentum

Bearish momentum

Value

2.4339

2.3796

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025